I-Isleworth Healthcare Acquisition Corp. kanye ne-Cytovia Holdings, Inc. namuhla bamemezele ukuthi bangene esivumelwaneni esiqinisekile sokuhlanganisa ibhizinisi. Lapho le nhlanganisela isiqediwe, i-Isleworth izoqanjwa kabusha ngokuthi i-Cytovia Therapeutics, Inc. (“inkampani ehlanganisiwe”) futhi isitoko sayo esivamile namawaranti kulindeleke ukuthi kuhlale kuhlu ku-NASDAQ ngaphansi kwezimpawu zamathikha i-INKC ne-INKCW, ngokulandelana.
Inkampani ehlangene izoqhubeka nokusebenza kwe-Cytovia futhi ihlale igxile ekuthuthukiseni nasekukhiqizeni amapulatifomu e-NK cell kanye ne-NK engager antibody.
Inkampani ehlanganisiwe izoholwa nguDkt. Daniel Teper, uMsunguli-kanye, uSihlalo, kanye noMphathi Omkhulu we-Cytovia.
“Sibonga kakhulu ukwesekwa ngabatshalizimali abasha nabakhona kanye nethimba losomabhizinisi asebemnkantshubomvu e-Isleworth. Silindele ukuthi lokhu kuthengiselana kusheshise ukwenziwa kombono we-Cytovia wokuthuthukisa imithi yokwelapha ye-NK iye ekwelapheni umdlavuza” kusho uDkt. Teper. "Sikhuthazwa imininingwane yethu yangaphambi komtholampilo esanda kwethulwa kwa-AACR, esekela ukuthuthukiswa kwamaseli ethu e-NK (iNK) asuselwa ku-iPSC (iNK) kanye ne-Flex-NK™ cell ekwelapheni i-Hepatocellular Carcinoma."
U-Bob Whitehead, oyi-CEO ye-Isleworth, uthe: “I-Isleworth ihlole izinkampani eziningi zesayensi yezempilo futhi yahlabeka umxhwele kakhulu ngethalente nobuchwepheshe obuhlanganiswe yiCytovia. Sikholelwa ukuthi i-Cytovia ingenye yezinkampani ezithuthuke kakhulu, ezintsha zelashwa ngamaseli ezihilelekile ekuthuthukisweni kwemithi emisha yokwelapha umdlavuza. Imithi yokwelapha amangqamuzana ku-oncology isivele ilethe ithemba ezigidini. Izindlela zikaCytovia zingenza izindlela ezifanayo zibe lula 'ngaphandle kweshalofu' futhi zithengeke.”
Indlela Yokwelapha ye-Cytovia
I-Cytovia ihlose ukusheshisa ukufinyelela kwesiguli ekwelapheni okuguquguqukayo kwamangqamuzana kanye ne-immunotherapies, ibhekana nezidingo zezokwelapha ezimbalwa eziyinselele ezingakafinyelelwa ku-oncology.
Le nkampani igxile ekusebenziseni amasosha omzimba azalwa nawo ngokwenza izinkundla ezisizayo neziphazamisayo ze-NK-cell kanye ne-NK-engager antibody. Ngokukhethekile, i-Cytovia ithuthukisa izinhlobo ezintathu zamaseli e-iNK: amaseli e-iNK angahleliwe, amaseli e-iNK ahlelwe yisakhi sofuzo e-TALEN® anomsebenzi othuthukisiwe nokuphikelela, namaseli e-TALEN® e-iNK ahlelwe yisakhi sofuzo anama-chimeric antigen receptors (CAR-iNKs) ukuze athuthukise ukucaciswa kwesimila. ukuqondisa. Ubuchwepheshe betshe legumbi lesibili obuhambisanayo inkundla ye-anti-specific multispecific quadrivalent edizayinelwe ukubandakanya amaseli e-NK ngokukhomba isamukeli esicupha i-NKp46 sisebenzisa ubuchwepheshe be-Flex-NK™ bokuphathelene.
Lezi zingxenyekazi ezimbili zobuchwepheshe zisetshenziselwa ukuthuthukisa ukwelashwa kweziguli ezine-Hepatocellular Carcinoma (HCC) kanye nezimila eziqinile. Izifundo zomtholampilo kulindeleke ukuthi ziqale ekupheleni kuka-2022.
Ikomkhulu e-Aventura, FL, iCytovia isebenzisa ilabhorethri ye-R&D e-Natick, MA kanye nesikhungo sokukhiqiza amaseli e-cGMP ePuerto Rico futhi inobambiswano besayensi ne-Cellectis, i-CytoImmune Therapeutics, i-Hebrew University of Jerusalem, i-INSERM, i-New York Stem Cell Foundation, iNational Cancer Institute, kanye neNyuvesi yaseCalifornia San Francisco (UCSF). I-Cytovia Therapeutics isanda kwenza i-CytoLynx Therapeutics, ubudlelwano obunamasu obugxile ocwaningweni nasekuthuthukisweni, ukukhiqiza, kanye nemisebenzi yokuthengisa e-Greater China nangale kwayo.
Ipayipi le-Cytovia
I-Cytovia iyinkampani yokuqala ye-immune-oncology enamandla okuhlanganisa isakhi sofuzo esithathwe yi-NK Cell ekhishwe yi-iPSC kanye ne-Flex-NK™ cell engager cell ukuze kuthuthukiswe isizukulwane esilandelayo se-immunotherapies yakho kokubili izicubu ze-hematological neziqinile.
Iphothifoliyo ye-Cytovia ihlanganisa okuhlosiwe kanye nezinkomba ezinephrofayili yobungozi elinganiselwe.
I-GPC3 iyinoveli ethembisayo ehloselwe izimila eziqinile, ikakhulukazi i-hepatocellular carcinoma, lapho isidingo sokwelashwa esingahlangatshezwana nayo sibaluleke kakhulu. Uhlelo oluholayo lwe-Cytovia luhlose ukuthuthukisa izindlela zokwelapha ze-HCC zesigaba sokuqala eziqondiswe ku-GPC3. Amakhandidethi emikhiqizo emine yokuqala azohlolwa njengemithi yokwelapha eyodwa futhi njengenhlanganisela yokwelapha. I-CYT-303, i-Cytovia's GPC3 Flex-NK™ engager, iyi-anti-specific antibody ebophezela kumaseli esimila se-HCC nge-GPC3 kanye namaseli e-NK nge-NKp46 ne-CD16a. Ezigulini ezinenombolo ekhubazekile noma umsebenzi wamaseli e-NK, i-Cytovia izohlola ukungezwa kwamaseli e-iNK, i-CYT-100, ukuze uvule amandla aphelele aleli su lokwelapha. I-Cytovia iphinde ithuthukise i-CYT-150, amaseli e-iNK ahlelwe ngofuzo, ukuze athuthukise ukungena kwesimila kanye nokuphikelela kwamangqamuzana, okungase futhi kuhlanganiswe ne-CYT-303. Ngaphezu kwalokho, i-CYT-503, i-GPC3-targeting CAR-iNK cell therapy, yakhelwe ukuthuthukisa ukucaciswa kokukhomba isimila. I-Cytovia ilindele ukufayela ama-IND e-CYT-303 kanye ne-CYT-100, alandelwe ama-IND e-CYT-150 kanye ne-CYT-503.
I-CD38 iyinkomba esungulwe kahle yomtholampilo neyohwebo ye-Multiple Myeloma. I-Cytovia yenza i-CYT-338 kanye ne-CYT-538, ngokulandelana, ama-CD38-targeting Flex-NK™ cell engagers kanye namaseli e-CAR-iNK okwelapha i-Multiple Myeloma ezigulini ezihlulekile ukwelapha ama-CD38 nama-ejenti aqondise ukuvuthwa kwamaseli e-B. i-antigen (BCMA).
I-Cytovia iphinde ithuthukise ikhandidethi le-EGFR CAR iNK elingena cranial ukuze likhombe kokubili i-wtEGFR ne-EGFR vIII ukuze ibhekane nesidingo esibalulekile sezokwelapha ekuphathweni kwe-Glioblastoma multiforme engelapheki njengamanje.
I-Cytovia isungule ukusebenzisana nezikhungo zemfundo kanye nozakwethu bemboni okuhlanganisa i-Cellectis yokuhlelwa kofuzo kwe-TALEN®. I-TALEN® ukuhlela izakhi kuwubuchwepheshe obusungulwe futhi bulawulwa yi-Cellectis, inkampani ye-biotechnology yesigaba somtholampilo esebenzisa inkundla yayo yokuhlela izakhi zofuzo ukuthuthukisa izindlela zokwelapha ezisindisa ukuphila nezakhi zofuzo. Amalungelo obunikazi e-TALEN® ahlelwa yi-Cellectis emkhakheni we-iNK kanye ne-CAR-iNK anikezwe ilayisense yakwa-Cellectis yi-Cytovia futhi i-Cytovia inamalungelo okuthuthukiswa komhlaba kanye nawokuhweba kulawa malungelo obunikazi.
Izinyathelo Ezihleliwe Ezihleliwe kanye Nokusetshenziswa Kwemali Ekhokhwayo
Inzuzo evela ezindaweni eziyimfihlo (“IPIPI”), izimali ku-akhawunti ye-trust ye-Isleworth (inani lemali etholakalayo), kanye nenzuzo evela kwezinye izimali ezingenzeka, ngesamba sesamba esingafika kumadola ayizigidi eziyikhulu, izonikeza i-Cytovia imali enkulu kufika ku-2 iminyaka ukuze ithuthukise ubuchwepheshe bayo be-iNK obuhlelwe ngofuzo kanye ne-Flex-NK™ cell engager. I-Cytovia ihlela ukugxila emiqondweni eminingi, okuhlanganisa:
• Ukufaka ama-IND amabili okuqala e-Flex-NK™ CYT-303 kanye ne-iNK CYT-100
• Ukuqala izivivinyo zomtholampilo zeSigaba I/II ukuhlola i-CYT-303 ne-CYT-100, iyodwa futhi ngokuhlangene, yokwelashwa kwe-HCC.
• Ukuthola nokwethula idatha yokuqala yomtholampilo ye-CYT-303 ne-CYT-100 ku-HCC
• Ukufaka ama-IND e-CYT-150 kanye ne-CYT-503 kanye nokuqalisa izivivinyo zomtholampilo zeSigaba I/II
• Ukuqhubeka nokuthuthukisa ubuchwepheshe be-iNK & Flex-NK™ nokuqhubekisela phambili umzila ngamakhandidethi amaningi okwelapha
